Lu JK, Wang W, Mahadzir MDA, Poganik JR, Moqri M, Herzog C, et al
Through this agreement, we aim to build on our experience targeting incretin biology to evaluate HS-10535 and its potential to provide additional cardiometabolic benefits beyond weight reduction. We are pleased to announce the in-license of our oral GLP-1 by Merck, a company with established leadership in cardiometabolic diseases, said Ms
Unexpectedly, we found that GLP-1 WT bound human FcRn 5-fold more strongly than unfused WT albumin at acidic pH, due to both faster association and slower dissociation
By bypassing the digestive system, IV administration allows for improved absorption and utilization of ALA